Possible move:52-100% Reward/Risk: 8-10 (R/R>3 is Ideal) Time frame: 1-2 wks This is just my technical view, not a fundamental comment..! I can make you confused by a crowded messy chart, but I would rather simple effective presentations..! Leave a comment that is helpful or encouraging. Let's master the markets together
look at the red consolidation boxes, TXMD tends to move sharply after making consolidation boxes! low risk, huge gain potential
After me! i will say no, i think this stock will not explode very soon but he have potential! Next weak we will se if we can break first resistence!
Gain Potential:30-75% Reward/Risk:4 Timeframe:1-4 wks
Contraceptives (just like vitamins and/or other medicine and supplements) are and always be crucial, no matter what is the economic situation. This is why I'm looking at and showing you TXMD. TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. We...
not an expert but i think this has explosive upside to it.
To keep it simple: the March crash brought around a strong consolidation in a triangle pattern within the lower segment (channel 3) of the longer-term, down-trending channel that the stock has stuck to for over five years now. Looks like it will jump upwards in early July. Previous larger drops on the decline have passed the support and gone into channel 4 here...
It should go up to the next Moving Average. Big gain possible. I will try to jump in on monday morning :)
All, I actually think .70 - .95 is actually a solid buy in here. Stop loss around 10% under just in case Purple = targets.. I think think first 3 should be no problem, but just in case. The top two are unlikely .. at least quickly.
Needs to pop above this lowering wedge, a pop above could push it to fill gap.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and...
Not really a household name among investors but well known to the ever growing of shorts. As of March 26th there was a 38% short interest. Despite FDA approval for 3 new drugs sales have been dismal and the company has increased expenditure on sales to tackle the issue, thus driving operating expenses much higher. The price currently sits at $4.57 well below the...
A long set up with a good profit to loss ratio. Stock has previously broken the 200 EMA. Appears to be starting a full-on uptrend. Best of luck.